Peripheral Nervous System Diseases
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.
Subtype terms (20)
More specific conditions that are subtypes of Peripheral Nervous System Diseases in the MeSH hierarchy.
- Acrodynia
- Amyloid Neuropathies
4 drugs (2 approved, 2 experimental)
- Brachial Plexus Neuropathies
3 drugs (2 approved, 1 experimental)
- Complex Regional Pain Syndromes
28 drugs (24 approved, 4 experimental)
- Diabetic Neuropathies
136 drugs (68 approved, 68 experimental)
- Giant Axonal Neuropathy
1 drug experimental
- Hand-Arm Vibration Syndrome
- Isaacs Syndrome
- Mononeuropathies
1 drug experimental
- Nerve Compression Syndromes
4 drugs (3 approved, 1 experimental)
- Neuralgia
159 drugs (90 approved, 69 experimental)
- Neuritis
14 drugs (7 approved, 7 experimental)
- Neurofibromatosis 1
55 drugs (44 approved, 11 experimental)
- Pain Insensitivity, Congenital
2 drugs approved
- Peripheral Nerve Injuries
45 drugs (29 approved, 16 experimental)
- Peripheral Nervous System Neoplasms
1 drug approved
- Polyneuropathies
29 drugs (22 approved, 7 experimental)
- Radiculopathy
62 drugs (40 approved, 22 experimental)
- Small Fiber Neuropathy
10 drugs (6 approved, 4 experimental)
- Tarlov Cysts
Drugs by status
Phase 4 trials (15)
Phase 3 trials (21)
Phase 2 trials (33)
- roflumilast
- metformin
- vitamin d3
- acalabrutinib
- adl5859
- vitamin e
- acetylcysteine
- benzatropine
- candesartan
- l-carnosine
- alpha-lipoic acid
- butylphthalide
- ethosuximide
- hydroxychloroquine
- hyaluronidase (human recombinant)
- mexiletine
- nicotine
- prosaptide
- ren-1654
- tetrodotoxin
- biotin
- cenplacel-l
- lacosamide
- methadone
- cilostazol
- selumetinib
- desloratadine
- rituximab
- daratumumab
- leteprinim
- +3 more
Phase 1 trials (5)
Other trials (27)
- acetylcarnitine
- t4p1001
- rimabotulinumtoxinB
- peptide t
- levobupivacaine
- pelargonium
- thiamine
- inactivated influenza vaccine
- autologous stromal vascular fraction
- menthol
- curcuma longa
- fentanyl
- oxygen
- corn
- mirogabalin
- mepyramine
- minocycline
- venlafaxine
- phenytoin
- methylfolate
- dextran 2-(diethylamino)ethyl ether
- fish oil
- Piper nigrum
- Zingiber officinale
- Mentha x piperita
- Rosmarinus officinalis
- Simmondsia chinensis
Organizations
Organization Involved with Phase 4 Indications (29)
- Eisai
- Gilead Sciences
- Pfizer
- Endo Pharmaceuticals
- Mundipharma
- Yung Shin Pharm. Ind. Co., Ltd.
- United States Navy
- Cardiovascular Institute of the South Clinical Research Corporation
- Duke University
- Tameside Hospital NHS Foundation Trust
- University of Kiel
- University of Toronto
- Taichung Veterans General Hospital
- University of Indonesia
- Government of Russia
- University of Maribor
- Catholic University of Korea
- Janssen Pharmaceutica NV
- Linkoping University
- Nema Research
- Aristotle University of Thessaloniki
- Universitaetsklinikum Schleswig-Holstein
- Johnson and Johnson
- University of Antwerp
- People's Liberation Army of China
- Krka
- Almazov National Medical Research Centre
- INTERBORA
- 3ARH
Organization Involved with Phase 3 Indications (71)
- Grunenthal
- Astellas
- Eli Lilly
- Octapharma
- Wyeth
- Chromaderm, Inc.
- GlaxoSmithKline
- GW Pharmaceuticals Ltd.
- Nihon Pharmaceutical Co., Ltd
- PledPharma AB
- Boehringer Ingelheim
- Solasia Pharma K.K.
- National Cancer Institute (NCI)
- Dr. Negrin University Hospital
- Maastricht University
- Cairo University
- University of London
- Cornell University
- Eastern Virginia Medical School
- Gynecologic Oncology Group
- Hoosier Cancer Research Network
- Mahidol University
- Mashhad University of Medical Sciences
- McGill University
- Nanjing Medical University
- New York University
- Northwestern University
- Seoul National University
- Southwest Oncology Group
- Sheffield Hallam University
- +41 more
Organization Involved with Phase 2 Indications (146)
- PPD
- AbbVie
- Convergence Pharmaceuticals
- Savient Pharmaceuticals
- Spectrum Pharmaceuticals
- Daiichi Sankyo
- Takeda
- Santhera
- XenoPort, Inc.
- Celgene
- Trophos
- Roche
- Aegera Therapeutics
- AstraZeneca
- Genentech
- Grifols
- Sanofi
- Biogen
- Aptinyx
- Novartis
- BioChemics, Inc.
- BioDelivery Sciences International
- Cebix Incorporated
- Cubist
- Dong-A Pharmaceutical
- Harrison Clinical Research
- Lexicon Pharmaceuticals
- Neurotune AG
- Ortho Biotech, Inc.
- Phoenix Neurological Associates, LTD
- +116 more
Organization Involved with Phase 1 Indications (16)
- Abide Therapeutics
- Actinogen Medical
- China Academy of Chinese Medical Sciences
- Eastern Regional Medical Center
- Fraser Health
- Ohio State University
- St. Luke's-Roosevelt Hospital Center
- Washington State University
- University of Colorado, Denver
- Allegheny Health Network
- Sangamo BioSciences
- University of Colorado
- TSPC America, Inc.
- Yuhan Pharmaceutical Company
- ARENSIA EXPLORATORY MEDICINE
- Shijiazhuang Pharma Group (CSPC)
Organization Involved with Other Experimental Indications (40)
- Amylin
- Advanced Peptides
- Forest Laboratories
- Pamlab
- SMR Biotech Co., Ltd.
- Tools4Patient
- Fondazione G.B. Bietti, IRCCS
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Huazhong University of Science and Technology
- Tri-Service General Hospital
- Academic and Community Cancer Research United
- Augusta University
- Benha University
- Temple University
- HealthPartners Institute
- Katholieke Universiteit Leuven
- Loma Linda University
- Oregon State University
- Physicians Committee for Responsible Medicine
- University of Hawaii
- University of Alberta
- Assiut University
- Taipei Medical University
- Emek Medical Center
- Al Azhar University
- Rush University
- University of Ljubljana
- Technion University
- Park Nicollet
- +10 more